Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

New England Journal of Medicine

Volumn 353, Issue 3, 2005, Pages 238-248

  Wanner, Christoph ^a,g   Krane, Vera ^a   März, Winfried ^b   Olschewski, Manfred ^c   Mann, Johannes F E ^d   Ruf, Günther ^e   Ritz, Eberhard ^f  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b General Hospital Southwest   (Austria)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Schwabing General Hospital   (Germany)

^e PFIZER INC   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATALITY; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; LIVER DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; MULTICENTER STUDY; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; TACHYCARDIA; BLOOD; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; INCIDENCE; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEART DISEASES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; PYRROLES; RENAL DIALYSIS;

EID: 22344458137     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa043545     Document Type: Article

References (29)

1. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57:640-51.
2. Armitage J, Bowman L. Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol 2004;15:439-46.
3. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
4. Schwenger V, Hofmann A, Kalifeh N, et al. Uremic patients - late referral, early death. Dtsch Med Wochenschr 2003;128: 1216-20. (In German.)
5. Koch M, Thomas B, Tschöpe W, Ritz E. Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993;36: 1113-7.
6. Renal Data System. USRDS 2003 annual data report: atlas of end-stage renal disease in the United States. Bethesda, Md.: National Institute of Diabetes and Digestive and Kidney Disease, 2003. (Accessed June 27, 2005, at http://www.usrds.org.)
7. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14:Suppl 4:S315-S320.
8. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002;61:1887-93.
9. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002;61:297-304.
10. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-52.
11. Lins RL, Matthys KE, Verpooten GA, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant 2003;18:967-76.
12. Wanner C, Krane V, Ruf G, März W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Kidney Int Suppl 1999;71:S222-S226.
13. Wanner C, Krane V, März W, et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D Study): demographic and baseline characteristics. Kidney Blood Press Res 2004;27:259-66.
14. Nauck M, Winkler K, März W, Wieland H. Quantitative determination of high-, low-, and very-low-density lipoproteins and lipoprotein( a) by agarose gel electrophoresis and enzymatic cholesterol staining. Clin Chem 1995;41:1761-7.
15. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
16. Tschöpe W, Koch M, Thomas B, Ritz E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis: results of a prospective study. Nephron 1993;64:354-8.
17. Koch M, Kuthuhn B, Trenkwalder E, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997;8:1889-98.
18. Schulgen G, Olschewski M, Krane V, Wanner C, Ruf G, Schumacher M. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials 2005;26:386-96.
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
20. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. [Erratum, Circulation 2004;110:763.]
21. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
22. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:Suppl 3:S112-S119.
23. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9: 1018-22.
24. Takayama F, Aoyama I, Tsukushi S, et al. Immunohistochemical detection of imidazolone and N(epsilon)-(carboxymethyl) lysine in aortas of hemodialysis patients. Cell Mol Biol 1998;44:1101-9.
25. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-38.
26. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
27. Mason NA, Bailie GR, Satayathum S, et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005;45:119-26.
28. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-63.
29. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:Suppl 1:S1-S266.